View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
May 13, 2020

Abbott’s Covid-19 test secures EUA for use on Alinity System

Abbott has received emergency use authorisation (EUA) from the US Food and Drug Administration (FDA) for its Covid-19 molecular test for use on its new Alinity m molecular lab system.


Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

Follow the latest updates of the outbreak on our timeline.


Abbott has received emergency use authorisation (EUA) from the US Food and Drug Administration (FDA) for its Covid-19 molecular test for use on its new Alinity m molecular lab system.

It is the fifth Covid-19 test developed by the company to receive FDA EUA.

Abbott is currently in the process of rolling out Alinity m molecular laboratory instrument to its US customers. The company is also working with hospitals and health systems in the country to install the new instrument that will help meet the growing demand for testing.

In March, the Alinity m system was cleared by the FDA for use with Abbott’s hepatitis C (HCV) assay.

Considered to be the company’s advanced laboratory molecular instrument, the automated platform provides laboratories with improved efficiency and flexibility by running more tests in less time.

Abbott president and CEO Robert Ford said: “Molecular lab tests play a critical role in detecting the virus for Covid-19. As a leader in diagnostics, we are pushing forward to develop high-performing tests across our platforms to help combat this pandemic.

“As we continue to develop and improve our testing technologies, we want to ensure they are meeting the needs of our customers and right now that means having reliable tests for Covid-19 on all of our diagnostic instruments.”

Up to 1,080 tests can be run on the Alinity m system in 24 hours, while the company’s m2000 RealTime system runs around 480 tests in the same time period.

Furthermore, the system provides labs with true random access, enabling them to run any test, any time for multiple infectious diseases while still delivering results within two hours.

It is especially critical during the Covid-19 pandemic when volume, speed and flexibility are needed, the company noted.

Related Companies

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network